Definium Therapeutics, Inc.
DFTX
$42.63
-$1.27-2.89%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -271.95% | -230.21% | -45.18% | -391.56% | -630.17% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 1,876.34% | 903.85% | 22.18% | 755.64% | 147.32% |
| Change in Net Operating Assets | -22.31% | 321.37% | -1,805.33% | 703.17% | 334.46% |
| Cash from Operations | -78.31% | -44.91% | -69.52% | -71.99% | -48.08% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -701.10% | 125.85% | -- | -- | -- |
| Cash from Investing | -701.10% | 125.85% | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | 320.00% |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 833,594.85% | 429.84% | 6,644.31% | -99.00% | -96.66% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -10,284.34% | -- | -21,161.33% | 100.00% | 78.89% |
| Cash from Financing | 3,779.22% | 429.84% | 6,358.31% | -98.92% | 82.15% |
| Foreign Exchange rate Adjustments | -104.00% | 125.00% | 0.00% | -90.91% | 2,400.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 894.04% | 102.45% | 1,204.20% | -125.76% | -437.63% |